Translate Bio’s MRTTM platform has the potential to change the lives of people living with debilitating genetic diseases.
Our goal is to continue building a leading, global mRNA therapeutics company that capitalizes on our extensive experience with proprietary mRNA product development, delivery, manufacturing and process development. We are primarily focused on applying our MRT platform to pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. Our lead program is being developed as a treatment for cystic fibrosis. We also believe our technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. We believe that our first-in-class MRT product candidates have the potential to transform these debilitating and life-threatening illnesses into manageable chronic conditions.
We plan to leverage the broad applicability of our MRT platform by developing additional MRTTM product candidates for our own pipeline. Specifically, we intend to:
- Maintain our initial focus on genetic diseases with high unmet medical need in the lungs to utilize our platform to rapidly develop new product candidates.
- Develop product candidates that address diseases with high unmet medical need.
- Leverage our existing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious diseases including a novel mRNA vaccine for SARS-CoV-2, the novel coronavirus responsible for the disease known as COVID-19.